What We Don't Yet Know About GLP-1s and Glucose in Non-Diabetics

Knowing the most includes knowing where the knowledge stops. Most GLP-1 content oversells certainty. This piece does the opposite, because naming the real gaps honestly is what separates trustworthy information from marketing. Three genuine holes define this field right now, and each one matters to you.

Gap 1: The prediabetes evidence is essentially empty

Here's the fact that surprises people. Almost all the evidence that GLP-1s reduce glucose variability comes from people with type 2 diabetes. For prediabetic and non-diabetic users, now the fastest-growing group taking these drugs, the controlled evidence on variability barely exists. A systematic search turns up a single mechanistic infusion study and no drug trials measuring CGM variability as an endpoint in this population (Behary 2019).

What that means in practice: when someone tells a non-diabetic user "this will lower your glucose variability," they're extrapolating from diabetes trials, not citing evidence in people like them. The mechanism makes it plausible (Thomas 2023), but plausible isn't proven, and honest content says so.

Gap 2: No head-to-head between tirzepatide and a GLP-1 on CGM

Tirzepatide (Mounjaro, Zepbound) adds GIP action to GLP-1 action, and it posts excellent CGM numbers, but only against insulin (Battelino 2022). No adequately powered trial has compared it directly with a GLP-1 receptor agonist using CGM metrics. So the question everyone asks, whether the dual drug actually gives steadier glucose than a single-pathway GLP-1, has no trial answer. The value of that second pathway, measured on a sensor, remains unmeasured.

Gap 3: Whether steadier glucose itself changes outcomes

Glucose variability is associated with cardiovascular disease, mortality, and atrial fibrillation (Martinez 2021; Li 2023). Association isn't causation. No trial has been designed to test whether reducing variability itself, as opposed to the weight and A1C changes that come with it, produces fewer hard outcomes. It's a reasonable hypothesis and an important one, but it stays untested. Anyone promising that flattening your glucose will prevent a heart attack is ahead of the evidence.

Why naming the gaps is the point

It would be easier to paper over these holes with confident language. The reader who wants to know the most is better served by the truth: the diabetes evidence is strong, the non-diabetic evidence is thin, the drug comparison is missing, and the causal question is open. Content that admits this is what clinicians and careful readers actually trust, and increasingly what gets cited when the answer matters.

What to do while the science catches up

If you're non-diabetic and curious about your glucose on a GLP-1, the move isn't to wait for the perfect trial. It's to observe your own response on a CGM and read it honestly. Your own data is valid for you even while the population-level questions stay open. Watch your curve, hold the marketing claims at arm's length, and let the evidence come in.

Three real gaps, then: a prediabetes evidence vacuum, a missing tirzepatide-vs-GLP-1 CGM trial, and an untested link between variability and outcomes. None of them are secret, and all of them are worth knowing. The most trustworthy thing anyone can tell you about GLP-1s and glucose in non-diabetics is exactly where the certainty ends.